Sara Coca Membribes, Clinical Research Fellow to Prof Powles at Barts Health NHS Trust, shared a post on X:
“Excited to have presented today at EAU26 on “New Therapeutic Options in Bladder Cancer“.
Personalised triplets in advanced disease are a major step forward but they’re only part of the story.
There’s promising activity for Izabren (dual EGFR/HER3, Topo1) in pretreated patients with ORR 44% and DCR 88%.
A randomised phase 2/3 is testing Iza vs platinum chemo in pretreated patients. Second generation ADCs are here to stay.
The story with 2nd generation ICI looks less compelling, with 2 notable exceptions.
VEGF-PD(L)1 bispecifics show synergistic effects with the most robust data coming from lung ca.
An early phase 1b/2 will test VEGF-PD-1 (SSGJ-707) +/- EV in mUC.
The other exception might be personalised vaccines and the adjuvant setting may be the ideal window as we target MRD.
Different early-phase trials are exploring adjuvant IO and customised neoantigen mRNA vaccines generated from each patient’s tumor mutations.
Last but not least, in NMIBC TAR-200 (SunRISe-1) is FDA-approved in BCG-unresponsive.
SunRISe-3 is testing TAR-200 +/- cetrelimab (PD-1) in BCG-naïve patients.
Will this strategy beat BCG I+M?”
Other articles featuring Sara Coca Membribes on OncoDaily.
